In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

In this video, Ursula A. Matulonis, MD, shares that although data from the REFRaME-O1 trial of luveltamab tazevibulin were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer ...

University of Kentucky Markey Cancer Center researchers presented ... approach to ovarian cancer maintenance therapy at the Society of Gynecologic Oncology annual meeting in Seattle (SGO 2025).

In this video, Ursula A. Matulonis, MD, discusses preliminary efficacy and safety results for puxitatug samrotecan in patients with recurrent endometrial cancer.Findings from a phase 1/2a study of ...

Overall, 44% of patients with a KRAS mutation in the phase 2 trial saw their tumors shrink, according to findings Dr. Grisham presented at the Society of Gynecologic Oncology Annual Meeting in March ...

The UAB Division of Gynecologic Oncology (GYN/ONC) serves as a major referral center for patients with gynecologic cancers in the state of Alabama, as well as the Southeast. We are a multidisciplinary ...